H6Z Stock Overview
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
YS Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.33 |
| Beta | 0.55 |
| 1 Month Change | 13.49% |
| 3 Month Change | 95.36% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| H6Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.7% | 0.8% | 1.2% |
| 1Y | n/a | -24.4% | 2.0% |
Return vs Industry: Insufficient data to determine how H6Z performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how H6Z performed against the German Market.
Price Volatility
| H6Z volatility | |
|---|---|
| H6Z Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: H6Z's share price has been volatile over the past 3 months.
Volatility Over Time: H6Z's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 754 | David Shao | www.ysbiopharm.com |
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.
YS Biopharma Co., Ltd. Fundamentals Summary
| H6Z fundamental statistics | |
|---|---|
| Market cap | €140.52m |
| Earnings (TTM) | -€43.02m |
| Revenue (TTM) | €70.17m |
1.9x
P/S Ratio-3.1x
P/E RatioIs H6Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H6Z income statement (TTM) | |
|---|---|
| Revenue | CN¥544.09m |
| Cost of Revenue | CN¥107.51m |
| Gross Profit | CN¥436.58m |
| Other Expenses | CN¥770.14m |
| Earnings | -CN¥333.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 80.24% |
| Net Profit Margin | -61.31% |
| Debt/Equity Ratio | 115.7% |
How did H6Z perform over the long term?
See historical performance and comparison